Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Improving immune checkpoint blockade (ICB) is crucial. One option is to use common anti-inflammatory drugs targeting the COX2/PGE2/EP2-4 pathway. They work well with ICB in mouse cancer models.
COX2 inhibitors or EP2-4 PGE2 receptor antagonists alone worked fast. They triggered a response. Combined with ICB, they increased effector T cells in tumors.
In patient-derived tumor fragments, a similar inflammatory shift has been seen. This favored T-cell activation.
Our findings highlight the COX2/PGE2/EP2-4 a…